Updated: September 19, 2020 6:34:45 pm
A research associate transfers medium to cells in the laboratory of Imperial College London. (AP Photo: Kirsty Wigglesworth)
Coronavirus Vaccine Tracker: The American biotech company Moderna has said it will learn of the effectiveness of its coronavirus vaccine in November. Moderna’s vaccine candidate is one of three large-scale Phase 3 clinical trials in the United States, enrolling 30,000 participants.
The company’s chief executive, Stephane Bancel, has said that if the candidate vaccine is determined to be at least 50 percent effective, the minimum bar set by the U.S. Food and Drug Administration to approve a vaccine will immediately request an emergency use authorization.
Bancel said that if all went well, the company could deliver around 100 million doses of vaccine to the US government in the “first months of 2021.”
The company also published a 135-page note on ongoing phase 3 trials. According to that note, which is dated August 20 but was released only on Thursday, the company expected to know the effectiveness of the candidate vaccine by December.
Moderna has never produced a vaccine that has been approved. For the coronavirus, you are using a genetic approach that has never produced a successful vaccine for any disease. But the company is trusted and backed by the U.S. government, which has contributed more than $ 1 billion to help the company accelerate vaccine development and has reserved hundreds of millions of doses when it is available.
Covid-19 Vaccine Tracker, Sept. 19 – Novavax Trials in India May Begin in October
Even if Moderna knows the effectiveness of its vaccine for November, it could be beaten in the race by another US pharmaceutical company, Pfizer, which has said it expected to be ready with effectiveness data by the end of October. Like Moderna, Pfizer is also conducting phase 3 trials of its vaccine in the United States. Pfizer has also said that it will request an emergency authorization once the effective data is available.
Along with AstraZeneca, the third vaccine in phase 3 trials in the US, Moderna and Pfizer are currently considered the first to produce a coronavirus vaccine.
📣 Express explained is now in Telegram. Click here to join our channel (@ieexplained) and stay up to date with the latest
More details emerge about a woman whose condition had stopped the AstraZeneca vaccine trial: a 37-year-old woman had confirmed a case of transverse myelitis
The woman whose severe illness had stopped global late-stage trials of a coronavirus vaccine being developed by AstraZeneca and the University of Oxford was a 37-year-old UK resident who developed serious complications after receiving the second dose of the vaccine. .
The woman was diagnosed with a confirmed case of transverse myelitis, a rare neurological disorder that affects the person’s spinal cord. The woman was hospitalized on September 5.
The details are contained in an “internal security report” prepared by AstraZeneca, which was obtained by CNN, which said the report was likely intended for the physicians who participated in the trials. AstraZeneca has not officially released details about the participant, other than saying that she had recovered from her ailment and had been released from the hospital.
Vaccine candidate AstraZeneca is considered one of the pioneers in the global race to develop a coronavirus vaccine. He was undergoing phase 3 trials in the United States, Brazil, and South Africa, and combined phase 2 and 3 trials in England and India, when news broke that the female participant became ill. The trials stopped in all places.
After a safety assessment in England, the trials were resumed. The go-ahead to restart trials has also been given in India. But the United States has ordered an investigation into this entire incident and has not yet decided to resume the trials.
Search for the coronavirus vaccine: the story so far
-
- 180 candidate vaccines in clinical or preclinical trials
- 35 of them in clinical trials
- Eight in final stages, phase III human trials
- At least eight potential vaccines are under development in India. Two of them have entered phase II trials after completing phase I.
The most commented:
* AstraZeneca / University of Oxford
* Modern
* Pfizer / BioNTech
* Johnson and Johnson
* Sanofi / GlaxoSmithKline
* Novavax
* Russian vaccine, developed by Gamaleya Insttiute in Moscow
(As of Sept.15; source: WHO Coronavirus Vaccine Overview Sept.9, 2020)
📣 The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay up to date with the latest headlines
For the latest news explained, download the Indian Express app.
© The Indian Express (P) Ltd
.
